NASDAQ:IMMU - Immunomedics Stock Price, Forecast & News

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

Immunomedics, Inc. (NASDAQ:IMMU) released its earnings results on Wednesday, October, 30th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.40) by $0.09. During the same quarter in the previous year, the business posted ($0.34) EPS. View Immunomedics' Earnings History.

Immunomedics is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Immunomedics.

9 analysts have issued 1-year price targets for Immunomedics' shares. Their forecasts range from $16.00 to $40.00. On average, they expect Immunomedics' share price to reach $27.33 in the next twelve months. This suggests a possible upside of 48.7% from the stock's current price. View Analyst Price Targets for Immunomedics.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunomedics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Immunomedics.

Headlines about IMMU stock have trended positive recently, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Immunomedics earned a coverage optimism score of 2.6 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Immunomedics.

Some companies that are related to Immunomedics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunomedics investors own include Celgene (CELG), Synergy Pharmaceuticals (SGYP), Seattle Genetics (SGEN), NVIDIA (NVDA), ImmunoGen (IMGN), Exelixis (EXEL), Iovance Biotherapeutics (IOVA), Micron Technology (MU), Netflix (NFLX) and ACADIA Pharmaceuticals (ACAD).

Immunomedics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Rhenman & Partners Asset Management AB (0.36%), Peregrine Capital Management LLC (0.36%), California Public Employees Retirement System (0.25%), Ironsides Asset Advisors LLC (0.02%), Tocqueville Asset Management L.P. (0.02%) and Strs Ohio (0.01%). Company insiders that own Immunomedics stock include Avoro Capital Advisors Llc, Bryan Ball, David M Goldenberg and Venbio Select Advisor Llc. View Institutional Ownership Trends for Immunomedics.

IMMU stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Rhenman & Partners Asset Management AB, Tocqueville Asset Management L.P. and Ironsides Asset Advisors LLC. View Insider Buying and Selling for Immunomedics.

IMMU stock was acquired by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, Strs Ohio, IFP Advisors Inc, Arden Trust Co and FTB Advisors Inc.. Company insiders that have bought Immunomedics stock in the last two years include Avoro Capital Advisors Llc, Bryan Ball and Venbio Select Advisor Llc. View Insider Buying and Selling for Immunomedics.

Shares of IMMU can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IMMU stock can currently be purchased for approximately $18.38.

Immunomedics has a market capitalization of $3.55 billion and generates $2.16 million in revenue each year. The biopharmaceutical company earns $-273,840,000.00 in net income (profit) each year or ($1.03) on an earnings per share basis. Immunomedics employs 346 workers across the globe.View Additional Information About Immunomedics.

The official website for Immunomedics is http://www.immunomedics.com/.

Immunomedics' mailing address is 300 AMERICAN RD, MORRIS PLAINS NJ, 07950. The biopharmaceutical company can be reached via phone at 973-605-8200 or via email at [email protected]